Magnesium augments immunosuppressive effects of a corticosteroid in obese mice with airway inflammation

Jundong Moon,1* Eun-Sang Cho,2 Mee-Young Lee,3 Hwa-Young Son,4 Kyoungyoul Lee1

Abstract

Background: Magnesium deficiency common in obesity is known to promote chronic low-grade inflammation and aggravate asthma symptoms; however, the effects of magnesium supplementation in obese asthmatic patients have not been investigated.

Objective: To examine the effects of magnesium co-administration with dexamethasone on airway inflammation in obese mice.

Methods: Female C57BL/6 mice were fed a high-fat diet, sensitized with ovalbumin (OVA) to induce allergic reactions, challenged with aerosolized OVA, and administered dexamethasone (3 mg/kg) with or without magnesium. Bronchial inflammation was analyzed based on the presence of inflammatory cells and cytokines in bronchoalveolar lavage fluid, total and OVA-specific IgE in serum, goblet cells ratios, bronchial wall thickness, and expression of α-smooth muscle actin.

Results: In obese mice, co-administration of magnesium and dexamethasone decreased IL-13 in bronchoalveolar lavage fluid and total and OVA-specific IgE in serum, and reduced α-smooth muscle actin-positive areas in the bronchi compared with mice treated with dexamethasone alone. However, no differences were observed in dexamethasone-treated normal-weight mice depending on magnesium supplementation.

Conclusion: These results suggest that magnesium increases immunosuppressive effects of dexamethasone in airway inflammation aggravated by obesity, suggesting that magnesium supplementation may have a potential in alleviating asthma symptoms in obese patients with reduced responses to corticosteroids.

Key words: magnesium deficiency, ovalbumin, asthma, obesity, chronic low-grade inflammation

Introduction

The incidence of obesity and asthma continues to rise worldwide and many epidemiological studies revealed positive correlation between excessive weight and asthma.1 It was found that the risk for newly diagnosed asthma in obese individuals within one year is 1.51 times higher than that in people with normal weight and increases proportionally with the body mass index.2 Obesity has been recognized as a global epidemic with a steadily increasing rate, and obesity-associated asthma has emerged as a major public health problem. Thus, a study conducted in North America found that approximately 75% of patients who visited the emergency room with acute asthma exacerbation are overweight or obese.3 Obese patients with severe asthma show blunted responses to steroids and β-agonists,4 and, thus, do not get sufficient relief during acute
asthma attack, indicating that new treatment approaches are urgently needed. Several hypotheses have been proposed regarding the association between obesity and asthma, including genetic predisposition and changes in lung mechanics such as reduction of lung compliance, expiratory reserve, and functional residual capacity caused by increased thoracic mass. It has also been suggested that chronic low-grade inflammation induced by adipokines, which are cytokines secreted by adipose tissue, contributes to the severity of asthma-related inflammation, ultimately promoting airway hyper-responsiveness.

Obesity is also a major risk factor for metabolic syndrome, and it has been suggested that obesity-associated deficiency of magnesium (Mg), one of the most important microelements with a role in the immune system, can potentially contribute to the underlying pathological mechanisms. Mg, which causes bronchial smooth muscle relaxation and acts as a weak bronchodilator, is used as an adjunct therapy for asthma treatment and, according to a Cochrane review of randomized clinical trials, can improve lung function in adult patients admitted to the emergency department with exacerbated asthma unresponsive to first-line therapies such as oxygen supplementation, β-agonists, and corticosteroids. Several reports suggest that the beneficial effect of Mg in asthmatic patients is underlain by the attenuation of excessive immune reactivity. However, most studies on the activity of Mg in asthma are clinical trials focused on physiological parameters such as respiratory rate, oxygen saturation, and forced expiratory volume 1 (FEV1), and health care quality indicators such as admission and discharge rates, whereas few studies addressed the effects of Mg on immune responses in asthma associated with obesity. As Mg deficiency is common for obese individuals, it may aggravate airway inflammation and compromise asthma treatment, suggesting that Mg supplementation may improve the effect of anti-inflammatory drugs such as corticosteroids in obstructive patients.

Therefore, in this study, we aimed to examine the effects of Mg co-administration with corticosteroids on immune response of obese and normal-weight mice after induction of bronchial inflammation.

**Materials and Methods**

**Animals and experimental protocol**

Specific pathogen-free female C57BL/6 mice (7-week-old; mean weight, 16.74 ± 0.26 g [control: 16.72 ± 0.2 g; obese: 16.76 ± 0.39 g]) were purchased from Orient Bio (Kyung-gi, Korea) and allowed to acclimatize in our animal facility under standard laboratory conditions for three days prior to experiments. Then, animals were randomly divided into normal diet group and high-fat diet group, which were provided either standard chow or high-fat (60% kcal) chow (D12492 Research Diet, New Brunswick, USA), respectively, and water ad libitum for 87 days.

To establish an allergic bronchial asthma model, OVA sensitization and airway challenge were performed as described previously. Mice were sensitized by intraperitoneal (i.p.) injection of 20 μg ovalbumin (OVA, grade III; Sigma-Aldrich, St. Louis, MO, USA) and 2 mg aluminum hydroxide in 200 μL PBS (pH 7.4) on days 120 and 127; PBS injection was used as negative control. After the initial sensitization, mice were exposed to 1% OVA solution (w/v in PBS) for 20 min using an ultrasonic nebulizer (NE-U12; Omron Corp., Tokyo, Japan), treated with dexamethasone (Dex; 3 mg/kg orally) alone or with MgSO4 (Mg; 100 or 200 mg/kg i.p.) on days 134, 135, and 136, and sacrificed on day 138. Overall, 10 treatment groups (5 groups per diet, n = 6 mice per group) were analyzed. The normal control (C) and obese (O) groups were respectively designated as: CP and OP, PBS-treated; CO and OO, OVA-treated; COD and OOD, OVA + Dex; CODM and OODM, OVA + Dex + Mg (100 mg/kg); CODM2 and OODM2, OVA + Dex + double Mg (200 mg/kg), as shown in Table 1.

<table>
<thead>
<tr>
<th>Allergen</th>
<th>Treatment</th>
<th>Group symbol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control mice (normal diet)</td>
<td>PBS</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>OVA</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>OVA</td>
<td>Dex</td>
</tr>
<tr>
<td></td>
<td>OVA</td>
<td>Dex + MgSO4 (100 mg/kg)</td>
</tr>
<tr>
<td></td>
<td>OVA</td>
<td>Dex + MgSO4 (200 mg/kg)</td>
</tr>
<tr>
<td>Obese mice (high-fat diet)</td>
<td>PBS</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>OVA</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>OVA</td>
<td>Dex</td>
</tr>
<tr>
<td></td>
<td>OVA</td>
<td>Dex + MgSO4 (100 mg/kg)</td>
</tr>
<tr>
<td></td>
<td>OVA</td>
<td>Dex + MgSO4 (200 mg/kg)</td>
</tr>
</tbody>
</table>

OVA, ovalbumin; Dex, dexamethasone (3 mg/kg).

The study protocol was approved by the Institutional Animal Care and Use Committee (IACUC) at Chungnam National University, and all procedures and methods were conducted in compliance with the regulations stipulated by the IACUC, the NIH Guidelines for the Care and Use of Laboratory Animals, and the National Animal Welfare Law of Korea.

**Inflammatory cell counts in bronchoalveolar lavage fluid (BALF)**

Mice were sacrificed with an overdose (50 mg/kg) of pentobarbital and blood was collected from the caudal vena cava. After tracheotomy, BALF was collected by instillation of 0.5 mL PBS three times through the tracheal cannula, centrifuged at 3,000 rpm for 10 min, and the supernatant was stored at -70°C until analysis. The total number of inflammatory cells was assessed by counting live and dead cells in a hemocytometer after trypan blue staining. Cell pellets were suspended in 0.5 mL PBS, and 100 μL of each solution was spread onto a slide using a cytopsin machine (Hanil Science Industrial, Seoul, Korea), dried, fixed, and stained with Diff-Quik Staining reagent (Merck, Darmstadt, Germany) according to the manufacturer’s instructions.
**Evaluation of total and OVA-specific IgE levels and cytokines**

Enzyme-linked immunosorbent assay (ELISA) kits were used to measure IL-4, IL-6, and IL-13 (Aviva Systems Biology, San Diego, CA, USA), serum leptin (Merck Millipore, Burlington, MA, USA), and total and OVA-specific IgE (Bethyl Laboratory, Montgomery, TX, USA) according to the manufacturers’ instructions.

**Histopathology analysis on lung tissue**

After BALF was obtained, lung tissues were fixed in 10% neutral-buffered formalin, embedded in paraffin, sectioned at 4-μm thickness, and stained with hematoxylin and eosin (H&E; Sigma-Aldrich) or periodic acid-Schiff (PAS; Merck) to assess inflammatory cell infiltration, mucus production, and bronchial wall thickness. The percentage of mucus-secreting cells was calculated according to the ratio of the area occupied by PAS-stained goblet cells to that of all epithelial cells. The thickness of the bronchial wall was calculated as previously described based on the measurements of the lumen diameter and the outermost layers of smooth muscle across the longest and the shortest perpendicular axis in circular or oval bronchi with diameters of 110–150 μm. Morphometric data were analyzed using Image J (NIH, Bethesda, MD, USA).

**Immunohistochemistry**

Lung tissue sections were deparaffinized, washed with 0.01 M PBS (pH 7.4), and treated with 0.1% hydrogen peroxide in methanol for 15 min to block endogenous peroxidase activity. After washing in PBS, sections were incubated with blocking buffer (1% bovine serum albumin) for 1 h and then with primary anti-α-smooth muscle actin antibodies (rabbit IgG; Abcam, Cambridge, UK) diluted 1:200 overnight at 4°C in a humidified chamber. Sections were warmed at room temperature, washed in PBS, and incubated with biotinylated goat anti-mouse IgG (Vector Laboratories, Burlingame, CA, USA) for 2 h, washed with PBS, and incubated with avidin-biotinylated complex (Vector Laboratories); 3,3′-diaminobenzidine (Sigma-Aldrich) was used to detect the signals. Sections were counterstained with hematoxylin, dehydrated, cleared, and mounted; actin-positive areas were photographed and measured using Motic Images Plus 2.0 (Motic China Co. Ltd, Xiamen, China). To correct for differences in bronchial size, actin-stained areas were normalized to the length of the basement membrane in sites with circular or oval bronchi of 110–150 μm in diameter.

**Statistical analysis**

The data were expressed as the mean ± standard error and statistically compared using Student’s t-tests and one-way analysis of variance (ANOVA) with Tukey’s post-hoc test; differences with P values less than 0.05 were considered significant. Statistical analyses were performed using SPSS version 21 (IBM, Chicago, IL, USA).

**Results**

**Induction of obesity by high-fat diet**

Mice fed high-fat diet gained significantly more weight and showed about 47% increase compared to control mice (32.55 ± 0.13 g versus 22.13 ± 0.07 g, respectively; P < 0.001); furthermore, they had significantly higher serum leptin levels compared to control mice (Figure 1), indicating successful establishment of an obesity model.

**Obesity enhances infiltration of eosinophils and lymphocytes into the lung**

Figure 2 presents immune cell counts in BALF. Compared with the CO and OO groups, mice treated with Dex and Mg had significantly lower neutrophil, eosinophil, and lymphocyte counts, whereas the reduction in macrophage counts was significant only in the CODM2 group compared to the CO group. There were no differences in inflammatory cell counts between groups treated with Dex alone or together with Mg either in normal or obese mice. The OO group had significantly higher counts of lymphocytes and eosinophils compared to the CO group, and the OODM2 group had significantly higher macrophage numbers compared to the CODM2 group.

![Figure 1. Effects of dexamethasone and Mg on serum leptin levels in normal and obese mice. *P < 0.05 compared with the corresponding group of normal mice.](image-url)
Figure 2. Effects of dexamethasone and Mg on the recruitment of inflammatory cells to bronchoalveolar lavage fluid. Mouse BALF was collected 48 h after final OVA challenge and stained using cytospin and Diff-Quik reagent. Cell numbers were counted within at least five hemocytometer squares under a light microscope. †P < 0.01 compared with the CP or OP group respectively; *P < 0.05 compared with the CO or OO group, respectively; ‡P < 0.05 compared with the corresponding group of normal mice.

Figure 3. Effects of dexamethasone and Mg on serum IgE levels. (A) Total IgE and (B) OVA-specific IgE. †P < 0.01 compared with the CP or OP group, respectively; *P < 0.05 compared with the CO or OO group, respectively; ‡P < 0.05 among OOD, OODM and OODM2 groups; †P < 0.05 compared with the corresponding group of normal mice.
Magnesium augments immunosuppressive effects of a corticosteroid in obese mice with airway inflammation

**Mg potentiates reduction of serum IgE by Dex in obese mice**

In mice fed normal diet, serum levels of total IgE (Figure 3A) and OVA-specific IgE (Figure 3B) were significantly lower for OVA-sensitized groups treated with Dex alone or together with Mg (COD, CODM, and CODM2) compared to the CO group. In obese mice, total IgE was also significantly lower in all Dex-treated groups (OOD, OODM, and OODM2), whereas OVA-specific IgE was significantly lower in the OODM2 group compared with the OO group. There was no significant difference in total and OVA-specific IgE among the COD, CODM, and CODM2 groups; however, in obese mice, the OODM2 group had significantly lower levels of total IgE compared to the OOD group and OVA-specific IgE compared to the OOD and OODM groups. Comparison between normal and obese mice revealed that the OOD and OODM groups had significantly higher total serum IgE levels than the corresponding control groups (COD and CODM).

**Mg promotes reduction of IL-13 levels in BALF of obese mice**

Measurements of pro-inflammatory cytokines in BALF (Figure 4) indicated that in normal mice, IL-4 levels were significantly lower in the COD and CODM2 groups and IL-6 levels were significantly lower in the COD group compared to control (CO). Among obese mice, IL-4 and IL-6 levels were decreased...
in the OOD, OODM, and OODM2 groups; however, these changes were not significant. In addition, IL-13 levels were significantly lower in the OODM and OODM2 groups compared to the OO group, indicating that among obese mice, only those treated with Mg had significantly lower IL-13 levels, whereas no differences in IL-13 were observed among normal-weight mice. Furthermore, mice in the OODM and OODM2 groups had significantly lower IL-13 levels compared with normal mice subjected to the same treatment.

**Mg administration did not influence mucus-secreting cells**

The proportions of mucus-secreting goblet cells known to proliferate in asthma significantly decreased in the lung epithelium of all Dex-treated normal and obese mice compared to respective OVA-sensitized groups, with the exception of the CODM group (Figure 5A). However, there were no significant differences between mice treated with Dex only (COD and OOD) and those receiving Dex and Mg (CODM and CODM2 or OODM and OODM2, respectively) or between obese and normal mice.

**Mg reduces hypertrophy of bronchial smooth muscle in obese mice**

The thickness of the bronchial wall was significantly decreased in all Dex-treated groups of both normal and obese mice, with the exception of the CODM group, and Mg co-administration did not produce significant differences compared with Dex alone (Figure 5B). Moreover, there were no differences between obese and normal mice of the corresponding groups. Immunohistochemistry analysis showed that the expression of α-smooth muscle actin assessed by measuring positively stained areas was significantly decreased in CODM as well as in OODM and OODM2 mice compared with untreated normal and obese mice (CO and OO groups, respectively) (Figure 5C). In obese
Magnesium augments immunosuppressive effects of a corticosteroid in obese mice with airway inflammation.

Figure 5. Effects of dexamethasone and Mg on airway wall. (A) The ratio of goblet cells to epithelial cells. (B) Airway wall thickness. (C) α-Smooth muscle actin-positive areas. ‡P < 0.01 compared with the CP or OP group, respectively; *P < 0.05 compared with the CO or OO group, respectively; #P < 0.05 between OOD and OODM groups.
mice, co-administration of Dex and Mg at a low dose (OODM) caused a significant decrease in α-smooth muscle actin staining compared with mice treated with Dex only (OOD). These data indicate that Mg could potentiate a positive effect of Dex on smooth muscle hypertrophy in obese mice with inflammation in the lungs.

The histopathology and immunohistochemistry images are presented in the Supplementary materials.

**Discussion**

Our findings show that obesity affected the severity of allergic airway inflammation and response to corticosteroid treatment in mice and that co-administration of Mg with Dex could reduce some inflammatory indices and bronchial smooth muscle cell proliferation in obese rather than in normal-weight mice.

In our model, obesity was induced by high-fat diet as indicated by significant weight gain and increased leptin levels compared to normal mice. Bronchial inflammation was stimulated by OVA as evidenced by increase in total and OVA-specific IgE levels and was somewhat stronger in obese than in normal mice judging by eosinophil and lymphocyte counts. However, these findings are at variance with those of Johnston et al., who showed a reduction in eosinophils in BALF and mononuclear cell counts. In the present study, treatment with Dex alone significantly decreased IgE, IL-4, and IL-6 levels in normal-weight mice but not in obese mice, in which it also did not significantly reduce the thickness of the bronchial wall. These results are consistent with previous findings that obesity increases the utilization of inhaled steroids and β-agonists, thus reducing the effectiveness of Mg co-administration on peripheral blood mononuclear cells to Dex observed in vitro. However, co-administration of Dex with Mg (200 mg/kg) could reduce total and OVA-specific IgE in obese mice. Furthermore, Mg at both doses could significantly augment the reduction of IL-13 and at a low dose could reduce smooth muscle areas compared to obese mice treated with Dex only. The immunosuppressive effects of Mg in obesity can be explained by its antagonism with Ca. Intracellular Ca influx, which is a prerequisite to increased production and secretion of pro-inflammatory factors, aggravates inflammation in the context of obesity and Mg deficiency and is known to enhance hyperplasia and hypertrophy of bronchial smooth muscle cells by promoting secretion of pro-inflammatory cytokines.

Studies on the clinical roles of Mg in obesity have typically been conducted in association with the metabolic syndrome that accompanies obesity and is manifested by insulin resistance, dyslipidemia, and hypertension. A clinical trial found that Mg supplementation reduced blood pressure in overweight adults with hypertension but did not affect that in individuals with normal blood pressure. Furthermore, oral Mg supplementation in adults improved bronchial response and the peak expiratory flow rate even without changes in Mg levels, suggesting that continuous Mg intake would have therapeutic effects in asthmatic patients because of increased demand for Mg. Therefore, Mg co-administration could be an effective treatment regimen for patients with subclinical Mg deficiency and chronic low-grade bronchial inflammation caused by obesity and asthma. Our findings showing the effectiveness of Mg co-administration with Dex only in obese mice are consistent with this hypothesis.

This study has some limitations. First, we did not directly measure Mg levels. A previous study reported Mg deficiency in 40% of patients with asthma. However, for accurate
assessments of Mg levels, they should be measured in serum, red blood cell, and urine as well as in the diet. Mg is an intracellular cation and its serum levels account for only about 1% of total Mg in the body; therefore, the intracellular level of Mg can be reduced without affecting that in serum, which makes it difficult to evaluate Mg deficiency and its clinical effects. Second, we did not have an experimental group receiving Mg only; therefore, it is unclear whether the effects of Dex + Mg co-administration are additive or synergistic. However, we believe that our model is clinically relevant because Mg has mild bronchodilating activity and is usually co-administered with steroids. Finally, although our study found that co-administration of Mg with DEX reduced the area of bronchial smooth muscle actin, the effect of Mg co-administration on bronchial remodeling could be more adequately assessed by prolonging the antigen exposure period. Leigh et al. compared bronchial remodeling during acute and chronic bronchial inflammation in mice and found different responses; thus, acute inflammation increased bronchial smooth muscle areas and goblet cell proliferation, whereas chronic inflammation increased deposition of extracellular matrix and airway hyper-responsiveness, which persisted for 8 weeks after challenge.

Conclusions
This study suggests that Mg co-administered with a steroid drug has immunosuppressive effects by decreasing some inflammatory indices and blocking bronchial smooth muscle cell proliferation in mice with obesity-associated allergic airway inflammation. These results should be validated in clinical trials to confirm that Mg supplementation could be a new therapeutic strategy for obesity-associated asthma.

Conflict of interest
The authors declare no competing financial interests.

References